New Indications for TIPSs: What Do We Know So Far?

被引:6
|
作者
Lapenna, Lucia [1 ]
Di Cola, Simone [1 ]
Gazda, Jakub [2 ,3 ]
De Felice, Ilaria [1 ]
Gioia, Stefania [1 ]
Merli, Manuela [1 ]
机构
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[2] Safarik Univ, Dept Internal Med 2, Kosice, Slovakia
[3] L Pasteur Univ Hosp Kosice, Kosice, Slovakia
关键词
transjugular intrahepatic portosystemic shunt; portal hyperten-sion; surgery; portal vein thrombosis; Budd-Chiari syndrome; INTRAHEPATIC PORTOSYSTEMIC SHUNT; PORTAL-VEIN THROMBOSIS; PARACENTESIS PLUS ALBUMIN; BUDD-CHIARI-SYNDROME; CIRRHOTIC-PATIENTS; REFRACTORY ASCITES; HEPATIC-ENCEPHALOPATHY; RISK-FACTOR; NONHEPATIC SURGERY; LIVER-CIRRHOSIS;
D O I
10.1016/j.jceh.2023.01.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Since 1988, transjugular intrahepatic portosystemic shunt (TIPS) has been an effective therapy for portal hypertension in many settings. Thanks to continuous technical improvements and a wiser selection of patients, excellent results have been achieved with this therapeutic strategy. The historical indications for TIPS placement, in the context of liver cirrhosis, such as refractory ascites and variceal bleeding are now well established and known. However, in recent years, new indications are emerging. These have been investigated and approved in some studies but are not yet included in guidelines and clinical practice. This review aims to highlight what is new for the role of TIPS in portal vein thrombosis (especially in patients awaiting liver transplantation), in recurrent ascites and not only refractory ascites, as a neoadjuvant therapy before abdominal surgery and, finally, in the setting of noncirrhotic portal hypertension. All these new aspects are addressed in this review with a critical approach based on the literature revision and clinical practice. Future research is needed to explore and validate the new role of TIPS in these scenarios. ( J CLIN EXP HEPATOL 2023;13:794-803)
引用
收藏
页码:794 / 803
页数:10
相关论文
共 50 条
  • [41] What Do We Know So Far about Multigenerational Mobility?
    Solon, Gary
    ECONOMIC JOURNAL, 2018, 128 (612): : F340 - F352
  • [42] Clozapine for bipolar disorder: What do we know so far and what next?
    Kapczinski, Flavio
    Pfaffenseller, Bianca
    Dursun, Serdar M.
    de Azevedo Cardoso, Taiane
    BIPOLAR DISORDERS, 2021, 23 (02) : 115 - 116
  • [43] Vomocytosis: What we know so far
    Seoane, Paula I.
    May, Robin C.
    CELLULAR MICROBIOLOGY, 2020, 22 (02)
  • [44] Anabaenopeptins: What We Know So Far
    Monteiro, Patrick Romano
    do Amaral, Samuel Cavalcante
    Siqueira, Andrei Santos
    Xavier, Luciana Pereira
    Santos, Agenor Valadares
    TOXINS, 2021, 13 (08)
  • [45] So that we know, what to do
    Stehr, Nico
    INTERNATIONALE POLITIK, 2009, 64 (04): : 18 - 23
  • [46] Covid-19 and dizziness: what do we know so far?
    Mezzalira, Raquel
    BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY, 2022, 88 (03) : 287 - 288
  • [47] COVID-19 and Hematology—What Do We Know So Far?
    Harshwardhan Khandait
    Garima Gandotra
    Sonali Sachdeva
    Courtney A. Kramer
    Derek Nye
    Reshma Golamari
    Rohit Jain
    SN Comprehensive Clinical Medicine, 2020, 2 (12) : 2631 - 2636
  • [48] Diets for inflammatory bowel disease: What do we know so far?
    Serrano-Moreno, Clara
    Brox-Torrecilla, Noemi
    Arhip, Loredana
    Romero, Inmaculada
    Morales, Angela
    Luisa Carrascal, M.
    Cuerda, Cristina
    Motilla, Marta
    Camblor, Miguel
    Velasco, Cristina
    Breton, Irene
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2022, 76 (09) : 1222 - 1233
  • [49] Sleep disruptions and bone health: what do we know so far?
    Swanson, Christine M.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2021, 28 (04) : 348 - 353
  • [50] Social Media and Knowledge Sharing - What Do We Know So Far?
    Mladenovic, Dusan
    Krajina, Anida
    Kucharska, Wioleta
    PROCEEDINGS OF THE 5TH EUROPEAN CONFERENCE ON SOCIAL MEDIA (ECSM 2018), 2018, : 163 - 170